The discovery of a mechanism that leads to cancer-therapy resistance highlights the many ways that tumour cells can...
Originally shared by Manuela Casasoli
The discovery of a mechanism that leads to cancer-therapy resistance highlights the many ways that tumour cells can adapt to survive — and reveals the limitations of categorizing patients by their gene mutations.
The development of resistance to cancer therapy is a major predictor of patient mortality. Therefore, understanding resistance mechanisms is key to improving therapeutic outcomes. Writing in Nature, He et al. report their discovery of a resistance mechanism in ovarian-cancer cells that contain a mutant version of the BRCA1 gene.
He et al. (2018) DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells: https://www.nature.com/articles/s41586-018-0670-5
https://www.nature.com/articles/d41586-018-07188-1
The discovery of a mechanism that leads to cancer-therapy resistance highlights the many ways that tumour cells can adapt to survive — and reveals the limitations of categorizing patients by their gene mutations.
The development of resistance to cancer therapy is a major predictor of patient mortality. Therefore, understanding resistance mechanisms is key to improving therapeutic outcomes. Writing in Nature, He et al. report their discovery of a resistance mechanism in ovarian-cancer cells that contain a mutant version of the BRCA1 gene.
He et al. (2018) DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells: https://www.nature.com/articles/s41586-018-0670-5
https://www.nature.com/articles/d41586-018-07188-1
Comments
Post a Comment